Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance

The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with lung adenocarcinoma (LUAD) harboring EGFR-activating mutations has resulted in a dramatic improvement in the management of the disease. However, the long-term clinical benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkountakos, Anastasios, Centonze, Giovanni, Vita, Emanuele, Belluomini, Lorenzo, Milella, Michele, Bria, Emilio, Milione, Massimo, Scarpa, Aldo, Simbolo, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869286/
https://www.ncbi.nlm.nih.gov/pubmed/35203491
http://dx.doi.org/10.3390/biomedicines10020277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869286/
https://www.ncbi.nlm.nih.gov/pubmed/35203491
http://dx.doi.org/10.3390/biomedicines10020277

Ejemplares similares